HOME >> MEDICINE >> NEWS
Preclinical results of Geovax's AIDS vaccines demonstrate potential to protect against disease

GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, today reported successful results from a preclinical trial using GeoVax's vaccines for the therapeutic treatment and prevention of Acquired Immunodeficiency Disease Syndrome ("AIDS") in non-human primates. The data demonstrate the effectiveness of GeoVax's DNA/MVA vaccines in controlling the Simian ("SIV") AIDS virus through immune responses raised by the vaccines. These promising results have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax's vaccines.

In this trial, two monkeys were infected with the SIV AIDS virus and then placed on drug therapy. Thereafter, once early drug therapy had temporarily reduced virus levels, the monkeys were vaccinated with the SIV version of GeoVax's DNA/MVA vaccines. Six weeks after vaccination, drug treatment was discontinued. The SIV virus levels temporarily rose in the vaccinated individuals, but were later "controlled" (reduced to much lower levels) by immune responses raised by the vaccines.

The reduction of virus levels in the blood stream of these AIDS virus-infected non-human primates has continued for more than a year to date. Vaccination with the GeoVax DNA/MVA vaccines has curtailed the development of AIDS and its associated debilitating effects, resulting in healthy, asymptomatic individuals. The monkeys have gained weight and have not required any additional drug therapy.

"The results of this trial demonstrate the long-term promise of our vaccines in treating HIV-AIDS," said Don Hildebrand, CEO of GeoVax Labs. "Our preclinical trials, coupled with encouraging data from two ongoing human trials, help validate the science behind our vaccines and provide the impetus for accelerating the planning of Phase II human trials for our preventive vaccines."

The ability to vaccinate those already infected with the AIDS virus, thereby inhibiting the virus' progressive and de
'"/>

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508
Financial Relations Board
6-Feb-2007


Page: 1 2

Related medicine news :

1. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
2. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
3. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
4. Targeted, oral agent Enzastaurin shows favorable results
5. Childhood obesity intervention shows promising results
6. Alpharma presents positive pharmacokinetic study results
7. UCSF brain tumor vaccine trial shows promising results
8. The eyes have it -- Autism research yields surprising results
9. ACP: Residency match results for internal medicine underscore need to redesign primary care
10. Positive results more likely from industry-funded breast cancer trials
11. Leading advocates express support for microbicide research, despite disappointing trial results

Post Your Comments:
(Date:7/29/2014)... survivors of severe combat injuries threatening more than one ... good record of safety and effectiveness in avoiding amputation, ... Plastic and Reconstructive Surgery , the official ... Surgeons (ASPS). , Experience with multiple limb salvage ... good success rates, with no increase in complications compared ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Chlorine helps keep pool ... likely to develop eye infections, doctors say. ... well as blurry vision, said Dr. Sampson Davis, an ... New Jersey. It,s important to understand why this ... away the outer film layer of the eye that ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According to ... of Time Magazine titled “From Kim’s Butt to Angelina’s ... Kardashian’s butt is the celebrity feature most requested ... features include Beyoncé’s butt, Jennifer Lawrence’s nose, ... information is based on data collected by an online ...
(Date:7/29/2014)... County, NJ (PRWEB) July 29, 2014 ... two leading pediatricians have joined our network, CarePoint ... Politis and Dr. Sushma Kaki. Hundreds of highly ... Group, a comprehensive network of top doctors and ... of specialties. This latest acquisition represents CarePoint Health’s ...
(Date:7/29/2014)... New high priced hepatitis C drugs will ... projected $2.9 to $5.8 billion next year, according to ... today by the Pharmaceutical Care Management Association (PCMA). Milliman ... as much as 8.6 percent in 2015 as a ... Olysio. , The study finds that the majority of ...
Breaking Medicine News(10 mins):Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
(Date:7/29/2014)... SALT LAKE CITY and ... EastGate Acquisitions Corporation (OTCBB: ESAQ), ... innovations in the development of improved novel ... biologically active molecules announces expansion of its ... company,s new development direction includes large molecule drugs ...
(Date:7/29/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes MobileHelp with the 2014 North ... Value Leadership. MobileHelp,s leadership in flexibility across in-home ... progression in personal emergency response, and exemplifies key ... MobileHelp is at the forefront of convenience ...
(Date:7/29/2014)... TAIPEI , July 29, 2014 Apex Medical ... Therapy and Pressure Area Care sectors, announces that it is ... Munich in Germany that ... patent. Apex notes that it has initiated invalidity challenges against ... continuous efforts in counterattacking against trivial and junk patents. ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Apex Continues Fighting Against Patents to Free Up Competition 2
Cached News: